Targovax ASA: Two abstracts accepted at the SITC Congress PR Newswire OSLO, Norway, Oct. 6, 2021 OSLO, Norway, Oct. 6, 2021 /PRNewswire/...
Targovax ASA appoints Ola Melin as Head of Manufacturing PR Newswire OSLO, Norway, Sept. 30, 2021 OSLO, Norway, Sept. 30, 2021 /PRNewswire/...
Targovax granted European Patent for ONCOS-102 in combination with chemotherapy PR Newswire OSLO, Norway, Sept. 24, 2021 Patent protection of...
Targovax granted European Patent for ONCOS-102 in combination with chemotherapy Patent protection of ONCOS-102 in combination with chemotherapy...
Targovax ASA: Poster at European Society for Medical Oncology (ESMO) PR Newswire OSLO, Norway, Sept. 16, 2021 Describing the role of ONCOS-102 in...
Targovax ASA: Poster at European Society for Medical Oncology (ESMO) Describing the role of ONCOS-102 in combination with aPD1 in aPD1...
Targovax ASA: Abstract on ONCOS-102 phase 1 trial in advanced PD1 refractory melanoma is accepted at ESMO Congress PR Newswire OSLO, Norway, Aug...
Targovax ASA: second quarter and first half year 2021 results PR Newswire OSLO, Norway, Aug. 18, 2021 OSLO, Norway, Aug. 18, 2021 /PRNewswire/...
Targovax to present at upcoming scientific conferences PR Newswire OSLO, Norway, Aug. 16, 2021 OSLO, Norway, Aug. 16, 2021 /PRNewswire/ ...
Targovax ASA: Invitation to presentation of Targovax's second quarter and first half 2021 results, Wednesday 18 August PR Newswire OSLO, Norway...
Targovax ASA appoints Dr Lone Ottesen as Chief Development Officer PR Newswire OSLO, Norway, July 1, 2021 OSLO, Norway, July 1, 2021 /PRNewswire/...
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Subscribe to Ad free and enjoy an ad-free experience
Try Now
Keep the Ads